Stock Analiz

Aclaris Therapeutics, Inc. ACRS

Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026

$3.92Market cap $622M
Open the interactive analysis →

Aclaris Therapeutics, Inc. (ACRS) is a healthcare company listed in the US with a market value of about $622M. In the twelve months to September 30, 2026 it had revenue of $6M and net income of -$80M, a net margin of -1244.1%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 4% a year, a 5-year average ROIC of -52%.

About Aclaris Therapeutics

Aclaris Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $2M in 2017 to $8M in 2025, growth of about 21.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 88% over three years (dilution for shareholders). It spends 673% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S97.1
P/B3.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-12.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-58.2%
Revenue growth (5 yrs, per year)3.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-690.9%
ROIC (5-yr avg.)-51.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$6M$8M$19M$31M$30M$7M$6M$4M$6M$2M—
Net income-$80M-$65M-$132M-$88M-$87M-$91M-$51M-$161M-$133M-$69M-$48M
Free cash flow-$75M-$47M-$20M-$80M-$68M-$52M-$39M-$98M-$102M-$56M-$35M
EPS (diluted)$-0.58$-0.53$-1.71$-1.27$-1.33$-1.60$-1.20$-3.90$-4.03$-2.44$-2.25
Net margin-1244.1%-829.6%-705.5%-283.2%-292.1%-1344.0%-787.0%-3817.2%-2158.0%-4071.5%—
ROIC—-57.4%-70.9%-60.3%-35.5%-35.4%-97.9%-118.6%-27.3%-23.5%-22.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 11 analysts is $10.36, 164% above the current price; targets range from $4.00 to $16.00; the consensus rating is “Strong buy”; expected EPS is $-0.60 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Aclaris Therapeutics pay a dividend?

Not currently.

Is Aclaris Therapeutics a good stock to buy?

We do not give buy or sell advice. Aclaris Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.